Related Experiment Video
Updated: Jul 15, 2026
05:10
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
Bioreductive drugs: from concept to clinic
S R McKeown1, R L Cowen, K J Williams
1Institute of Biomedical Sciences, University of Ulster, Coleraine, Northern Ireland BT52 1SA, UK. sr.mckeown@ulster.ac.uk
Clinical Oncology (Royal College of Radiologists (Great Britain))
|May 8, 2007
Summary
Bioreductive drugs target hypoxic tumor cells, enhancing radiotherapy and chemotherapy. Tirapazamine and Banoxantrone show promise, though clinical results vary, highlighting the need for targeted cancer therapies.
Area of Science:
- Radiobiology
- Pharmacology
- Oncology
Background:
- Hypoxia significantly impacts radiotherapy response.
- Bioreductive drugs are designed to selectively target hypoxic tumor cells.
- Four classes of bioreductive compounds (quinones, nitroaromatics, N-oxides) have been developed.
Purpose of the Study:
- To review the development and clinical application of bioreductive drugs for cancer treatment.
- To discuss the efficacy and toxicity of specific bioreductive agents in combination therapies.
- To evaluate the potential of novel bioreductive drugs in targeting hypoxic tumors.
Main Methods:
- Review of pre-clinical data and published clinical studies on bioreductive drugs.
- Analysis of drug activation mechanisms requiring hypoxia and specific reductases.
- Evaluation of combination therapy outcomes with radiation and standard chemotherapy.
Main Results:
- Tirapazamine (TPZ) has shown variable clinical efficacy and toxicity in over 20 trials.
- Banoxantrone (AQ4N) demonstrates promise in early trials with good tolerability and tumor localization.
- Mitomycin C (MMC) and its analogues have had mixed clinical success due to toxicity and targeting challenges.
Conclusions:
- Bioreductive drugs offer a targeted approach to enhance cancer treatment efficacy in hypoxic tumors.
- Further research and development are needed to optimize the clinical use of these agents.
- Balancing efficacy with toxicity remains a critical consideration for successful clinical translation.
Related Concept Videos
01:26Drug Discovery: Overview
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
01:16Drug Biotransformation: Overview
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
01:28Drug Biotransformation: Overview
Biotransformation, also known as drug metabolism, is a vital physiological process that chemically alters drugs, facilitating their elimination from the body and terminating their action. This process involves two main phases: phase I and phase II reactions. Phase I reactions, including oxidation, reduction, and hydrolysis, introduce or unmask polar functional groups on the drug molecule, thereby increasing its water solubility. By enhancing water solubility, the drug becomes more hydrophilic...
01:28Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
01:30Prodrugs
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Prodrugs help overcome...
01:22Bioreactor Controls-III
Strain improvement is a foundational strategy in industrial microbiology aimed at maximizing microbial productivity, particularly because natural isolates typically yield commercially valuable products in very low concentrations. Although optimizing the culture medium and environmental conditions can improve yields, these adjustments are inherently limited by the organism’s genetic potential. As a result, the focus shifts toward genetic modifications to enhance biosynthetic capacity. The...